Hostname: page-component-6766d58669-wvcvf Total loading time: 0 Render date: 2026-05-22T16:01:42.702Z Has data issue: false hasContentIssue false
  • English
  • Français

Prebiotic B-Galacto-oligasaccharide supplementation of the low FODMAP diet improves symptoms of irritable bowel syndrome but does not prevent diet induced decline in bifidobacteria: a randomised controlled trial

Published online by Cambridge University Press:  11 December 2017

B. Wilson ,
M. Rossi ,
G. Parkes ,
Q. Aziz ,
S. Anderson ,
P. Irving ,
M. Lomer  and
K. Whelan
B. Wilson
Affiliation:
King's College London, Diabetes and Nutritional Sciences Division, London, UK
M. Rossi
Affiliation:
King's College London, Diabetes and Nutritional Sciences Division, London, UK
G. Parkes
Affiliation:
Barts Health NHS Trust, Department of Gastroenterology, London, UK
Q. Aziz
Affiliation:
Barts Health NHS Trust, Department of Gastroenterology, London, UK
P. Irving
Affiliation:
Guy's and St Thomas’ NHS Foundation Trust, Department of Gastroenterology, London, UK
M. Lomer
Affiliation:
King's College London, Diabetes and Nutritional Sciences Division, London, UK Guy's and St Thomas’ NHS Foundation Trust, Department of Gastroenterology, London, UK
K. Whelan
Affiliation:
King's College London, Diabetes and Nutritional Sciences Division, London, UK
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Dietary restriction of fermentable oligo-, di-, mono -saccharides and polyols (low FODMAP diet, LFD) is widely used for the management of irritable bowel syndrome (IBS)( Reference Staudacher, Irving and Lomer 1 ), however it reduces gastrointestinal (GI) bifidobacteria( Reference Staudacher, Lomer and Anderson 2 ). B-galacto-oligosaccharide (B-GOS; HOST-G904) are prebiotics that increase bifidobacteria in IBS( Reference Silk, Davis and Vulevic 3 ). The combination of the two therapies has not previously been investigated.

This randomised controlled trial aimed to investigate whether: 1) IBS symptoms improved on LFD supplemented with 1·4 g/d B-GOS compared to control; and 2) B-GOS supplementation (1·4 g/d) could prevent the reduction of GI bifidobacteria seen in patients following the LFD.

Adults fulfilling Rome criteria for IBS were screened for inclusion (n = 130). Sixty-nine patients were recruited to a 3-arm parallel RCT and were randomised to: control (sham diet/placebo), LFD only (LFD/placebo) or LFD plus B-GOS (LFD/B-GOS). Validated questionnaires were used to assess GI symptoms and stool output. Stool were analysed for bifidobacteria using fluorescent in situ hybridisation, and short-chain fatty acids (SCFA) and pH were measured using gas chromatography and pH probe respectively.

Adequate relief of IBS symptoms differed significantly between control (30·4 %), LFD (50 %) and LFD/B-GOS (66·7 %) (p = ·046), with differences specifically between control and LFD/B-GOS (p = ·015). Individual IBS symptoms were more markedly improved in the LFD/B-GOS group compared to control. Bifidobacteria (log10/g dry weight) also differed across the groups (control 9·8, LFD 9·6, LFD/B-GOS 9·5; p = ·009), with the LFD/B-GOS significantly lower than control (P = ·009). In the intervention groups higher stool pH at seven days (p = 0·008) and four weeks (p = 0·004), and lower butyrate at seven days (p = 0·002) and four weeks (p = 0·004) was observed.

Symptoms of IBS markedly improved during LFD supplemented with B-GOS prebiotic, suggesting a synergy between the two therapies however addition of a low-dose prebiotic does not overcome the effect of diet on bifidobacteria. Luminal markers of bacterial metabolism reveal LFD significantly impacts the GI luminal environment within the first seven days and these changes persist with diet restriction.

References

1. Staudacher, HM, Irving, PM, Lomer, MC et al. (2014) Gastroenterol Hepatol, 11, 256–66.Google Scholar
2. Staudacher, HM, Lomer, MC, Anderson, JL et al. (2012) J Nutr 142, 1510–8.CrossRefGoogle Scholar
3. Silk, DBA, Davis, A, Vulevic, J et al. (2009) Aliment Pharmacol Ther 29, 508–18.CrossRefGoogle Scholar